Kimia Biosciences
- Market cap
- ₹ 141 Cr.
- P/E
- 19.9x
- P/B
- 8.02x
- 52-week range
- 23.2 – 43.28
- ROE
- 54%
- ROCE
- 25%
- Dividend yield
- 0%
- Debt / equity
- 1.96
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- BSE
About
Kimia Biosciences Limited is an India-based company, which is engaged in the manufacturing of bulk drugs addressing various high-potential therapeutic segments. The Company provides its products under various categories: Commercial Active Pharmaceutical Ingredients (APIs), and Commercial KSMs, Intermediates and Reagents. The Company's Commercial-APIs products include Acotiamide Hydrochloride Hydrate, Azelnidipine, Benfotiamine, Benidipine Hydrochloride, Citicoline Sodium, Gliclazide, Dapagliflozin Propanediol Monohydrate, Levosulpiride, Luliconazole, Oxaceprol, Prucalopride Succinate, Teneligliptin Hydrobromide Hydrate, Vildagliptin, Fimasartan Trihydrate Potassium, Obeticholic Acid, Ursodeoxycholic Acid and others. Its Commercial KSMs, Intermediates and Reagents products include Ethyl-2-Amino 1,3-Thiazole 4-Carboxylate; 2,4,5-Trimethoxy Benzoic Acid; Ethyl 2-(2,4,5-trimethoxybenzamido)-1,3-thiazole-4-carboxylate; Choline phosphate chloride calcium, and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Kimia Biosciences against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)19.9 against a typical 34.3: cheaper than most peers (1st = cheapest).59th of 220
- Sales growth−12.1% against a typical +15.6% from a year earlier.170th of 197
- Profit growth−40% against a typical +18.9% from a year earlier.127th of 160
- Share price, 3 months−2.5% against a typical −0.5%.110th of 200
- Size₹ 141.5 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).133rd of 199
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 24 | 26 | 30 | 22 | 28 | 30 | 38 | 24 | 34 | 30 | 27 | 21 |
| Expenses | 26 | 27 | 26 | 19 | 25 | 25 | 30 | 21 | 31 | 24 | 25 | 18 |
| Operating Profit | −2 | −1 | 4 | 4 | 3 | 5 | 8 | 3 | 3 | 7 | 3 | 2 |
| OPM % | −8.1% | −4% | 13.7% | 16.6% | 12% | 16.6% | 21.4% | 10.7% | 7.4% | 21.8% | 9.8% | 11.3% |
| Other Income | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | −0 | 0 | 1 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | −3 | −3 | 2 | 2 | 2 | 4 | 6 | 1 | 1 | 5 | 2 | 0 |
| Tax % | −25.2% | −25% | 22.2% | 19.7% | 15.7% | −27.3% | 68.6% | 13% | −7.4% | −7.7% | 79% | 26.5% |
| Net Profit | −2 | −2 | 2 | 1 | 2 | 5 | 2 | 1 | 1 | 5 | 0 | 0 |
| EPS in Rs | −0.52 | −0.41 | 0.38 | 0.3 | 0.34 | 0.97 | 0.42 | 0.13 | 0.22 | 1.15 | 0.08 | 0.08 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 90%
- 5 Years
- −3%
- 3 Years
- −4%
- TTM
- −7%
- 10 Years
- 14%
- 5 Years
- 8%
- 3 Years
- 43%
- TTM
- −18%
- 10 Years
- 14%
- 5 Years
- −10%
- 3 Years
- −9%
- TTM
- —
- 10 Years
- —
- 5 Years
- −1%
- 3 Years
- 54%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Kimia Biosciences | ₹ 30.25 | ₹ 141 Cr. | 19.9x | 8x | 54% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 37.1x | 5.4x | — | 19.8% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 94.3x | 14.8x | — | 26.1% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 74.4x | 19.7x | — | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21x | 4.2x | — | 15.7% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 26.8x | 3.2x | — | 11.9% |
Management
- Sameer Goel
- Executive Chairman of the Board, Chief Executive Officer, Managing Director
- Abhishek Kumar Pandey
- Compliance Officer, Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.